By Alex Ababio | Special Investigative Report
Ghana has spent years producing scientific papers, developing promising formulations and building pharmaceutical expertise. The harder question has always been what happens after the research is published.
Can a discovery move from a university laboratory into a factory, pass regulatory scrutiny, survive clinical testing, win market approval and ultimately reach a Ghanaian pharmacy or hospital?
That question now sits at the centre of a €2 million research-to-manufacturing initiative that the government and its international partners hope will help change Ghana’s pharmaceutical economy.
Speaking in Accra at the “Research Meets Manufacturing” award ceremony, Health Minister Kwabena Mintah Akandoh challenged researchers not to measure success by publications or laboratory discoveries alone.
“Your research must not end on laboratory shelves or in academic journals. It must travel the full distance towards products that improve lives,” he said, according to the Ghanaian Times report of the ceremony published on August 21, 2026.
The warning goes to the heart of Ghana’s pharmaceutical challenge: scientific capacity exists, but translating that capacity into commercially viable, regulator-approved products at scale remains much more difficult.
The €2 million experiment
Eight Ghanaian research-and-development projects have received grants under the PharmaVax Ghana Programme, with funding ranging across medicines, vaccines, biological products, diagnostics and herbal medicine.
The projects were selected from 43 proposals by an independent committee of nine Ghanaian experts, according to the account of the award ceremony. Ghanaian project partners are also putting up a combined €425,000 of their own resources.
The programme is part of the broader Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (MAV+). GIZ says PharmaVax Ghana is co-financed by Germany’s Federal Ministry for Economic Cooperation and Development (BMZ) and the European Union and is designed to strengthen Ghana’s pharmaceutical ecosystem.
Importantly, this is not simply a research-grant programme. The original GIZ call required applicants to form partnerships between Ghanaian research institutions and Ghanaian pharmaceutical manufacturers. Projects could cover drug discovery, formulation development, clinical trials and other applied R&D activities, with grants of up to €125,000, €300,000 or €500,000 for projects lasting up to 24 months.
That structure matters because it attempts to address one of the weakest links in African pharmaceutical innovation: the distance between the scientist who develops a product and the company capable of manufacturing it.
Eight bets on Ghanaian science
The funded portfolio covers a strikingly broad range of health priorities.
KNUST, working with Aspee Pharmaceuticals Limited and the Ghana Atomic Energy Commission, received €300,000 to scale up a locally developed herbal pain medicine for sustainable manufacturing.
The University of Cape Coast, partnering Kash Chemist Limited, received €100,000 for development of a fast-dissolving oral tablet for malaria treatment in children, with the objective of improving dosing accuracy.
The Noguchi Memorial Institute for Medical Research at the University of Ghana, together with Atlantic Lifesciences Limited, received the largest individual award—€500,000—to generate stability data intended to support regulatory approval of locally produced tetanus-diphtheria vaccines and tetanus antitoxin.
The CSIR-Water Research Institute, with Kantanka Herbal Pharmaceuticals and Research Centre, received €125,000 to build scientific evidence around herbal treatment for alcohol-related liver disease.
The Centre for Plant Medicine Research, working with Dodowa Health Research Centre and Atlantic Lifesciences, secured a combined €340,000 across two projects involving a clinical trial of a herbal product for prostate health and stability testing for locally produced snake-venom antiserum with an extended shelf life.
The West African Centre for Cell Biology of Infectious Pathogens at the University of Ghana, partnering DEK Vaccines Limited, minoHealth AI Labs and INCAS Diagnostics & Services, received €300,000 to apply a Ghanaian AI platform to the design and scale-up of monoclonal antibodies and diagnostics for Mpox and malaria.
And Central University, with Ernest Chemists Limited, received €250,000 to develop and validate a standardised herbal treatment for hypertension.
Together, these projects represent a deliberate attempt to connect universities, research institutions, pharmaceutical manufacturers and technology companies rather than allowing research to remain isolated within academia.
Why the stakes are bigger than Ghana
The initiative arrives against a stark continental reality.
A WHO global vaccine-manufacturing analysis published in 2025 found that the WHO African Region procured less than 5% of its vaccine doses from manufacturers headquartered within Africa, while more than half of vaccine volumes came from suppliers headquartered in India.
A peer-reviewed analysis published in BMJ Global Health similarly found that, as of 2023, only about 1% of vaccines deployed in Africa were manufactured on the continent.
The vulnerability was exposed dramatically during COVID-19—and again during the Mpox crisis, when African countries struggled to secure vaccines despite facing a major public-health emergency. Reuters reported in 2024 that the first shipment of Mpox vaccines to Africa arrived only after years of limited access, illustrating how dependent African health systems remained on external manufacturers and donors.
Ghana’s vaccine ambitions therefore sit within a much larger African movement toward health security and industrial sovereignty.
The National Vaccine Institute (NVI) was established in 2023 with a mandate covering the institutional arrangements for vaccine research, development and manufacturing. NVI Chief Executive Officer Dr Sodzi Sodzi-Tettey has described public-private partnerships as central to Ghana’s manufacturing strategy, including collaboration with Ghanaian companies such as Atlantic Lifesciences and DEK Vaccines.
But manufacturing is not the same as self-sufficiency
Ghana’s pharmaceutical ambitions confront a difficult economic reality.
A recent World Bank assessment estimates the local manufacturers’ market share at roughly 30–40%, while noting that exact data are unavailable. It says increasing that share to 70% would require investment in more cost-effective production methods and higher volumes to compete with imports, particularly from India and China.
The same assessment identifies structural pressures including expensive imported inputs, high financing costs, technological limitations and shortages of specialised skills.
This is why the Minister’s challenge goes beyond simply telling scientists to “commercialise” their work.
A promising medicine still has to demonstrate quality, safety, efficacy and stability. A vaccine requires highly specialised production systems, stringent quality controls and regulatory oversight. A diagnostic product needs validation. A herbal medicine needs credible evidence that satisfies regulators and clinicians, not merely traditional claims.
GIZ itself identifies governance and regulation, skills development, research and development, and private-sector development as the four pillars of PharmaVax Ghana.
That architecture suggests the programme recognises that money for research alone cannot build a pharmaceutical industry.
The market question could decide everything
Perhaps the most important development is that government procurement could become a bridge between research funding and commercial manufacturing.
At the Accra ceremony, Minister Akandoh disclosed that the government’s framework contract for medicines and related products was estimated at approximately GH¢159 million, with plans to increase it. He argued that such arrangements could provide a stronger market for locally manufactured medicines and encourage investment.
This is potentially significant.
Pharmaceutical companies cannot sustainably manufacture at scale without predictable demand. Researchers cannot successfully commercialise discoveries if manufacturers have no confidence that there will be buyers. And manufacturers will struggle to invest in sophisticated facilities if public procurement continues to favour imported products irrespective of quality and local capacity.
The challenge, however, will be ensuring that procurement decisions remain transparent, competitive and anchored in quality and value for money.
The regulatory test
The real test of PharmaVax will therefore begin after the ceremony.
The projects must produce credible scientific evidence. Clinical studies must meet ethical and regulatory requirements. Manufacturing facilities must meet applicable quality standards. Products must obtain approval from Ghana’s Food and Drugs Authority where required. Intellectual property arrangements must be clear. Manufacturing costs must be competitive enough for products to survive beyond donor funding.
And consumers must ultimately trust the products.
Ghana is already building regulatory capacity for the emerging vaccine-manufacturing ecosystem. The FDA has been working with stakeholders on quality-assurance systems, including risk-based vaccine lot-release processes, as Ghana prepares for local vaccine manufacturing.
The programme is also investing in the human capital required for the sector. In March 2026, the University of Health and Allied Sciences announced a strategic engagement with GIZ under PharmaVax Ghana to strengthen vaccine workforce training involving pharmacists, pharmaceutical scientists, biomedical scientists, laboratory experts, industry professionals and regulatory specialists.
From grant recipients to products
German Ambassador to Ghana Frederik Landshöft said the eight projects demonstrate the potential of Ghana’s research and pharmaceutical sectors, while urging beneficiaries to take their innovations beyond laboratories into clinical trials, production lines, hospitals and pharmacies. Ghanaian partners are contributing another €425,000 alongside the €2 million grant envelope.
EU Chargé d’Affaires and Head of Political Section Jonas Claes also reaffirmed European support for Ghana’s research, innovation and pharmaceutical manufacturing ambitions.
But the strongest measure of success will not be the number of dummy cheques handed over in Accra.
It will be whether a child eventually receives a Ghana-developed malaria formulation; whether a locally manufactured vaccine passes regulatory approval and enters routine supply; whether a Ghanaian diagnostic reaches hospitals; whether a herbal medicine moves from traditional use to scientifically validated treatment; and whether Ghanaian companies can manufacture these products competitively enough to sell them across West Africa.
That is the real investigation now facing Ghana.
The country has funded research before. It has produced researchers before. It has established pharmaceutical manufacturers before.
PharmaVax is attempting to connect all three.
The Minister has drawn the line clearly: research cannot remain trapped in laboratories.
The next question is whether Ghana’s universities, manufacturers, regulators, investors and government procurement system can carry those discoveries all the way to the market.
If they can, the €2 million programme could become more than a collection of research grants. It could become an important building block in Ghana’s attempt to reduce pharmaceutical import dependence, retain more economic value domestically and establish itself as a West African centre for medicines and vaccine manufacturing.
If they cannot, the country risks adding another chapter to a familiar African story: promising science that never quite makes the journey from the laboratory shelf to the patient.